BACKGROUND: Cystatin C, a novel marker of renal function, has been associated with heart failure and cardiovascular mortality in older individuals. We tested the hypothesis that cystatin C is associated with preclinical cardiac structural and functional abnormalities in a younger population-based sample. METHODS AND RESULTS: The study included participants in the Dallas Heart Study (ages 30 to 65 years) who had measurements of cystatin C and cardiac MRI. The associations of cystatin C with left ventricular (LV) mass, LV end-systolic and -diastolic volumes, concentricity (LV mass/LV end-diastolic volume), LV wall thickness, and LV ejection fraction were evaluated. Cystatin C levels ranged from 0.46 to 6.55 mg/L. In univariable analyses, increasing levels of cystatin C correlated with higher LV mass, concentricity, and wall thickness (P<0.001), but not with LV end-systolic volume, LV end-diastolic volume, or LV ejection fraction. After adjustment with traditional covariates and estimated glomerular filtration rate by the modification of diet in renal disease formula, log-transformed cystatin C remained independently associated with LV mass (P<0.001), concentricity (P=0.027), and wall thickness (P<0.001). These associations persisted when creatinine or estimated glomerular filtration rate by the Cockcroft-Gault formula were included in the models. CONCLUSIONS: Higher levels of cystatin C were associated with increased LV mass and a concentric LV hypertrophy phenotype. These findings were independent of potential confounding variables including standard measurements of renal function, supporting the hypothesis that cystatin C may be useful to identify individuals with preclinical structural heart abnormalities.
BACKGROUND:Cystatin C, a novel marker of renal function, has been associated with heart failure and cardiovascular mortality in older individuals. We tested the hypothesis that cystatin C is associated with preclinical cardiac structural and functional abnormalities in a younger population-based sample. METHODS AND RESULTS: The study included participants in the Dallas Heart Study (ages 30 to 65 years) who had measurements of cystatin C and cardiac MRI. The associations of cystatin C with left ventricular (LV) mass, LV end-systolic and -diastolic volumes, concentricity (LV mass/LV end-diastolic volume), LV wall thickness, and LV ejection fraction were evaluated. Cystatin C levels ranged from 0.46 to 6.55 mg/L. In univariable analyses, increasing levels of cystatin C correlated with higher LV mass, concentricity, and wall thickness (P<0.001), but not with LV end-systolic volume, LV end-diastolic volume, or LV ejection fraction. After adjustment with traditional covariates and estimated glomerular filtration rate by the modification of diet in renal disease formula, log-transformed cystatin C remained independently associated with LV mass (P<0.001), concentricity (P=0.027), and wall thickness (P<0.001). These associations persisted when creatinine or estimated glomerular filtration rate by the Cockcroft-Gault formula were included in the models. CONCLUSIONS: Higher levels of cystatin C were associated with increased LV mass and a concentric LV hypertrophy phenotype. These findings were independent of potential confounding variables including standard measurements of renal function, supporting the hypothesis that cystatin C may be useful to identify individuals with preclinical structural heart abnormalities.
Authors: Fernando L Martin; Paul M McKie; Alessandro Cataliotti; S Jeson Sangaralingham; Josef Korinek; Brenda K Huntley; Elise A Oehler; Gerald E Harders; Tomoko Ichiki; Sarah Mangiafico; Karl A Nath; Margaret M Redfield; Horng H Chen; John C Burnett Journal: Am J Physiol Regul Integr Comp Physiol Date: 2011-11-09 Impact factor: 3.619
Authors: Anna Clementi; Grazia Maria Virzì; Ching Yan Goh; Dinna N Cruz; Antonio Granata; Girogio Vescovo; Claudio Ronco Journal: Cardiorenal Med Date: 2013-04 Impact factor: 2.041
Authors: Ann B Nguyen; Anand Rohatgi; Christine K Garcia; Colby R Ayers; Sandeep R Das; Susan G Lakoski; Jarett D Berry; Amit Khera; Darren K McGuire; James A de Lemos Journal: Arterioscler Thromb Vasc Biol Date: 2011-08-04 Impact factor: 8.311
Authors: Jeanney Lew; Monika Sanghavi; Colby R Ayers; Darren K McGuire; Torbjørn Omland; Dorothee Atzler; Maria O Gore; Ian Neeland; Jarett D Berry; Amit Khera; Anand Rohatgi; James A de Lemos Journal: Circulation Date: 2017-02-07 Impact factor: 29.690
Authors: Anand Rohatgi; Andrew W Owens; Amit Khera; Colby R Ayers; Kamakki Banks; Sandeep R Das; Jarett D Berry; Darren K McGuire; James A de Lemos Journal: Arterioscler Thromb Vasc Biol Date: 2009-10 Impact factor: 8.311
Authors: Matthew Nayor; Martin G Larson; Na Wang; Rajalakshmi Santhanakrishnan; Douglas S Lee; Connie W Tsao; Susan Cheng; Emelia J Benjamin; Ramachandran S Vasan; Daniel Levy; Caroline S Fox; Jennifer E Ho Journal: Eur J Heart Fail Date: 2017-02-20 Impact factor: 15.534
Authors: Tammy M Brady; Kelly Townsend; Michael F Schneider; Christopher Cox; Thomas Kimball; Peace Madueme; Bradley Warady; Susan Furth; Mark Mitsnefes Journal: Am J Kidney Dis Date: 2016-11-14 Impact factor: 8.860
Authors: Juan I Pérez-Calvo; Marta Sánchez-Marteles; Francisco-José Ruiz-Ruiz; José-Luis Morales-Rull; José-Antonio Nieto-Rodríguez Journal: JRSM Short Rep Date: 2010-10-21